Eurofins stock advances as 9M growth improves sequentially
Published on 10/29/2026 at 17:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth improves while guidance softens
- Eurofins reported EUR 5.614 billion in revenue for the first nine months of 2026.
- Organic growth accelerated through the first three quarters, but the company expects full-year growth below its previous objective.
- Profitability and cash-flow objectives remain unchanged, including a 24 percent adjusted EBITDA margin target for 2027.
Eurofins Scientific reported improving sequential growth in the first nine months of 2026, while acknowledging that its full-year organic-growth objective is unlikely to be reached. The update was published on October 21, 2026, in a Eurofins press release.
Sequential improvement continues
Reported revenue reached EUR 5.614 billion in the first nine months, an increase of 3.7 percent from the prior-year period. Organic growth rose from 2.5 percent in the first quarter to 3.0 percent in the second and 3.5 percent in the third quarter.
The company said third-quarter progress included broad-based acceleration in BioPharma, mid-single-digit growth in BioPharma Product Testing and a return to positive growth at Discovery and Genomics. Growth remained uneven across regions, with the rest of the world outperforming Europe and North America over the nine-month period.
What has changed since the last report
The operating message is familiar from the latest company update, but the market reference has moved higher. Eurofins traded at EUR 85.72 at Lang & Schwarz on October 27, 2026, at 10:10 a.m. CEST, in the most recent relevant report read for comparison. The licensed Lang & Schwarz quote was EUR 86.81 on October 29, 2026, at 16:30:06 Berlin time, an increase of 1.27 percent since that report.
The quote is a Lang & Schwarz reference and is not a verified Xetra closing comparison. Investors can track the real-time quote of Eurofins Scientific stock.
Margin targets remain intact
Eurofins expects full-year 2026 organic growth to remain below its previous mid-single-digit objective because market conditions stayed slower than normal and some clinical programs are not expected to restart this year. It nevertheless kept its 2026 profitability and cash-flow objectives unchanged, expects acquisition revenue to exceed the previous annualized EUR 250 million objective and retained its 24 percent adjusted EBITDA margin objective for 2027.
Eurofins Scientific stock facts
- Company: Eurofins Scientific SE
- ISIN: FR0014000MR3
- Ticker: ERF
- Primary exchange: Euronext Paris
- Lang & Schwarz price: EUR 86.81 on October 29, 2026, at 16:30:06 Berlin time
- Sector: Healthcare / Medical Diagnostics and Research
Market conditions remain an important variable for the CAC 40, while Eurofins investors are also watching the execution of acquisitions, laboratory investments and digitalisation projects.
